Please login to the form below

Not currently logged in
Email:
Password:

European recommendation for Galvus' monotherapy license

CHMP issues positive opinion for Novartis' diabetes drug

Novartis has won backing from European regulatory advisers for a monotherapy licence for its type II diabetes drug Galvus (vildagliptin).

This would allow the drug to be used on its own in patients whose diabetes is inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.

The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on extending the drug's current licence as a dual oral therapy.

At the moment it can only be used in combination with metformin, a sulphonylurea (if metform is inappropriate) or a thiazolidinedione in patients with insufficient glycaemic control.

CHMP positive opinions are normally passed as full European approval within three months, and would give a further boost to Galvus, which is also marketed in Europe under the brand names Jalra and Xiliarx.

The diabetes drug recently extended its licence in Europe, winning approval to treat type two diabetic patients with either moderate or severe renal impairment.

19th December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics